Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finolizumab plus chemoradiotherapy as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2600117897Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of finotonlimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Pathologic Complete Response (pCR). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
finotonlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600117897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117897.